Evidence-informed pharmacology monograph, updated 10 November 2026. For medical education; individual management requires current product labeling and qualified clinical assessment.
Overview
Quinidine is a cinchona alkaloid and class IA antiarrhythmic with sodium-channel blocking and repolarization-prolonging effects. Although historically used for atrial and ventricular arrhythmias, its use today is limited by torsades de pointes, adverse effects and evidence of increased mortality in some patients treated for non-life-threatening arrhythmias. Its use must be distinguished from quinine-based antimalarial treatment [1,2].
Mechanisms of action
Quinidine blocks fast cardiac sodium channels, slowing phase-0 depolarization and conduction, and inhibits repolarizing potassium currents, prolonging action potential duration and QT. Antimuscarinic activity can paradoxically increase AV conduction in atrial flutter or fibrillation, so appropriate AV-nodal rate control and rhythm selection matter. Quinidine also inhibits P-glycoprotein, increasing exposure to several interacting drugs [1].
Clinical context and restricted role
Routine prophylaxis of atrial fibrillation recurrence or suppression of benign ventricular ectopy is generally disfavored owing to an unfavorable risk-benefit balance. Rare specialist uses may exist for particular inherited electrical disorders or difficult arrhythmias, but these should not be generalized to all patients. Quinidine is not a standard contemporary malaria prophylaxis drug, and claims that it has a broad therapeutic index are incorrect [1,2].
Pharmacokinetics
Quinidine is absorbed orally, with hepatic metabolism including CYP3A4 pathways and variable renal elimination. Formulations, protein binding, kidney/liver function and interacting medications influence exposure. Blood levels and ECG findings can inform specialist management where available, but there is no universally safe serum concentration independent of clinical context [1,2].
Serious adverse effects
Quinidine can cause QT prolongation and torsades de pointes, syncope, hypotension, AV block, gastrointestinal upset and cinchonism (tinnitus, headache, visual or auditory disturbances). Immune thrombocytopenia and other rare serious effects are possible. US labeling cites increased mortality in meta-analyses of prophylactic treatment for atrial fibrillation/flutter and certain non-life-threatening ventricular arrhythmias. Monitor QT/QRS, heart rhythm, kidney/liver function and symptoms [2].
Critical interactions
Quinidine can increase serum digoxin concentrations substantially by reducing its clearance and altering distribution; digoxin dose and concentration monitoring may require adjustment. Interactions with other QT-prolonging agents, CYP3A4 inhibitors/inducers, neuromuscular blockers and electrolyte disturbances can cause harm. Correct hypokalemia or hypomagnesemia and review existing antiarrhythmics before any specialist use [1,2].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- DailyMed. Quinidine sulfate tablets, USP: prescribing information, warnings about mortality, torsades and digoxin interactions. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b0d6341b-d880-4f0b-8844-bc788c03004a
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.